<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Transient hypogammaglobulinemia of infancy</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Transient hypogammaglobulinemia of infancy</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Transient hypogammaglobulinemia of infancy</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ilan Dalal, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Chaim M Roifman, CM, MD, FRCPC, FCACB</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jordan S Orange, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elizabeth TePas, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 12, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Transient hypogammaglobulinemia of infancy (THI) was classically described as an accentuation and prolongation of the "physiologic" immunoglobulin nadir that is normally observed during the first three to six months of life  (<a class="graphic graphic_figure graphicRef99496" href="/d/graphic/99496.html" rel="external">figure 1</a>) [<a href="#rid1">1,2</a>]. However, there remains no full agreement among immunologists regarding the definition of THI due to the absence of specific markers or a genetic signature. While some use sweeping inclusion criteria such as a reduction in any immunoglobulin (immunoglobulin G [IgG], immunoglobulin A [IgA], immunoglobulin M [IgM]), beyond the physiologic nadir [<a href="#rid2">2-7</a>], most agree that low IgG is essential for considering the diagnosis [<a href="#rid8">8-12</a>].</p><p>This topic reviews the clinical features, diagnosis, and management of THI. Other humoral immune defects are reviewed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/3914.html" rel="external">"Primary humoral immunodeficiencies: An overview"</a>.)</p><p class="headingAnchor" id="H3284825663"><span class="h1">DEFINITIONS</span><span class="headingEndMark"> — </span>The definition proposed by the International Union of Immunological Societies (IUIS) committee [<a href="#rid13">13</a>], calling for obligatory low IgG and IgA in THI, poses multiple challenges. It excludes all cases of isolated, transient low IgG (4 to 45 percent of cases of classically defined THI [<a href="#rid3">3,8,10,14</a>]) and also includes other entities such as hyper-IgM syndrome and common variable immunodeficiency (CVID) [<a href="#rid15">15</a>].</p><p>The European Society for Immunodeficiencies (ESID) has proposed the term "unclassified hypogammaglobulinemia" for children in the first three years of life with low IgG levels, reserving THI for those children that recover by age four years [<a href="#rid16">16</a>]. The ESID definition includes children with borderline low IgG levels.</p><p>The authors of this topic use a more conservative definition, which, on one hand, is flexible enough to include most cases historically considered to have THI but sufficiently restrictive to prevent confusion with other possible conditions. It encompasses low serum IgG levels in the presence or absence of low IgA or IgM (consistent with the ESID criteria) and normalization of IgG levels, as well as specific antibodies (if low initially), over time [<a href="#rid17">17</a>]. Hypogammaglobulinemia associated with a reduction in circulating B cells, abnormal cellular immunity, and syndromic features is excluded from the definition of THI.</p><p class="headingAnchor" id="H1023930105"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>The estimated incidence of THI, using the more conservative definition, is between 0.061 and 1.1 per 1000 live births [<a href="#rid4">4,18</a>]. Some cohorts demonstrated a disproportionate number of male infants (up to 70 percent) [<a href="#rid3">3,14,19</a>], but this finding was not supported by other studies [<a href="#rid12">12,20,21</a>].</p><p class="headingAnchor" id="H8"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>The molecular basis underlying THI remains elusive [<a href="#rid2">2,8-10,22-29</a>], although there are ongoing attempts to determine the pathogenesis of this disorder.</p><p>A defect in B cell CD19 expression was proposed as a possible cause of reduced immunoglobulin production in THI in a single study [<a href="#rid30">30</a>]. However, other groups have found increased numbers of circulating CD19<sup>+</sup> B cells in patients with THI [<a href="#rid31">31</a>]. This discordant result may be explained by the difference in study populations. The first study was performed on a highly consanguineous population, while the second study was done on a presumed genetically heterogeneous North American group. A CD19 defect as a cause for THI is also challenged by the findings that B cell development and in vitro immunoglobulin production are normal in THI [<a href="#rid11">11,32</a>] but not in CD19 deficiency [<a href="#rid33">33</a>]. In addition, CD5<sup>+</sup> B cells are normal in THI but low in CD19 deficiency [<a href="#rid30">30</a>].</p><p>Alternatively, a reduced immunoglobulin switch defect was found by some investigators [<a href="#rid33">33,34</a>] but not others [<a href="#rid35">35</a>]. However, this theory cannot be reconciled with the normal in vitro immunoglobulin production [<a href="#rid23">23</a>] and the temporary nature of THI [<a href="#rid34">34</a>]. Similarly, an abnormality in the Fc gamma receptor does not appear to underlie the transient low IgG levels [<a href="#rid34">34</a>].</p><p class="headingAnchor" id="H9"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>The clinical manifestations of THI have remained consistent in large surveys and prospective studies [<a href="#rid15">15,19,36</a>]. Most patients suffer upper and lower respiratory tract infections (40 to 90 percent), and the second most common feature is allergic disorders (approximately 30 to 50 percent). Rare manifestations include urinary tract infections, gastroenteritis, and invasive infections [<a href="#rid19">19,20,30</a>], as well as developmental delay and cardiac defects [<a href="#rid31">31</a>].</p><p class="headingAnchor" id="H1023930934"><span class="h2">Recurrent or unusual infections</span><span class="headingEndMark"> — </span>Most infants with THI are identified because immunoglobulin measurement was performed due to a history of recurrent infections starting early in life. The spectrum of infections ranged from recurrent upper respiratory infections (URIs), otitis media, bronchitis, and urinary tract infections to severe, invasive infections, such as bacteremia and bacterial meningitis [<a href="#rid9">9,19,21-23</a>]. The initial indication for immunologic evaluation was recurrent URIs in one-half of these patients. Other indications included recurrent gastroenteritis, severe varicella, and prolonged oral thrush [<a href="#rid8">8</a>].</p><p class="headingAnchor" id="H10"><span class="h2">Atopic features</span><span class="headingEndMark"> — </span>Atopic manifestations are frequently reported in patients with THI [<a href="#rid4">4,6-8</a>]. These include increased immunoglobulin E (IgE) concentrations and food allergy [<a href="#rid37">37</a>]; symptoms of either atopic disease or food allergy/intolerance without a history of recurrent infections [<a href="#rid18">18</a>]; and severe eczema (along with sensitization to certain common food allergens) that resolved with systemic glucocorticoids, relapsed with topical corticosteroids, and ultimately resolved with normalization of IgG levels [<a href="#rid38">38</a>].</p><p class="headingAnchor" id="H1563286105"><span class="h2">Asymptomatic</span><span class="headingEndMark"> — </span>Some infants with THI are asymptomatic, and the diagnosis is recognized because they had an immune evaluation, including screening of serum immunoglobulin levels, due to a family history of primary immunodeficiency [<a href="#rid4">4,25</a>].</p><p class="headingAnchor" id="H1023929469"><span class="h1">LABORATORY FINDINGS</span><span class="headingEndMark"> — </span>The laboratory hallmarks of THI include the following:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Serum immunoglobulins</strong> – IgG is at least two standard deviations (SDs) below the mean for age-matched controls, with or without diminished levels of IgA or IgM. There is some variability in normal levels and SDs at different institutions and diagnostic laboratories.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Specific antibodies</strong> – Most patients with THI have normal antibody responses to infections or to immunizations at presentation, while the remainder normalize by the time of resolution of THI [<a href="#rid12">12,31</a>]. In addition to normal antibodies found against protein antigens (such as tetanus), antipolysaccharide antibodies also appear comparable with controls in most [<a href="#rid4">4,5,26</a>], but not all [<a href="#rid8">8,16</a>], children. (See  <a class="medical medical_review" href="/d/html/3929.html" rel="external">"Assessing antibody function as part of an immunologic evaluation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immunophenotyping and T cell function</strong> – Most studies have found intact lymphocyte subpopulations, including the level of memory and class-switched B cells [<a href="#rid5">5,8,9,22,26</a>]. In addition, studies have shown normal in vitro responses to mitogens [<a href="#rid5">5,8,9,22,26</a>] and normal production of IgG [<a href="#rid23">23</a>]. There are some cases of contrary findings; however, those patients may have other classified immunodeficiencies rather than THI. As examples, a single study reported transient numeric and functional abnormalities of CD4<sup>+</sup> T cells [<a href="#rid23">23</a>], and a few other single-center studies have described lower or higher than normal expression of CD19 expressing B cells [<a href="#rid30">30,31</a>]. Another group identified reduced numbers of circulating IgM<sup>+</sup> and "switched" (IgM<sup>-</sup>IgD<sup>-</sup>) memory B cells and an inability to produce IgG in vitro in some patients [<a href="#rid15">15,39</a>], a feature commonly observed in common variable immunodeficiency (CVID) [<a href="#rid11">11,40,41</a>]. Another group reported that, while the proportion of regulatory T cells (Tregs) in children with THI were significantly increased compared with controls, primary memory B cells were reduced. Additionally, the proportion of CD127 in CD3<sup>+</sup> and CD3<sup>+</sup>CD4<sup>+</sup> T cells were significantly reduced in patients with THI compared with controls [<a href="#rid42">42</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hematologic abnormalities</strong> – Hematologic manifestations are uncommon. Transient neutropenia was reported in two series [<a href="#rid4">4,8</a>], and a case of permanent neutropenia and another patient who developed acute lymphoblastic leukemia were also reported [<a href="#rid8">8</a>].</p><p></p><p class="headingAnchor" id="H15"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of THI cannot be made at presentation but rather is made retrospectively. It is one of several possible diagnoses considered in the heterogeneous population of young children presenting with recurrent infections and low immunoglobulins.</p><p>The diagnosis is dependent upon obligatory criteria:</p><p class="bulletIndent1"><span class="glyph">●</span>Serum IgG level must be recorded at more than two standard deviations (SDs) below age-matched controls with or without diminished levels of other serum immunoglobulins on at least two occasions.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Immunoglobulins, as well as specific antibody formation, must normalize, usually during childhood or rarely during adolescence.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other defined immunodeficiencies, as well as syndromes, should be excluded. (See <a class="local">'Differential diagnosis'</a> below.)</p><p></p><p>In order to establish the diagnosis, the following assessment is required:</p><p class="bulletIndent1"><span class="glyph">●</span>History of type of past infections and a thorough physical examination (to exclude syndromes). (See  <a class="medical medical_review" href="/d/html/3903.html" rel="external">"Laboratory evaluation of the immune system"</a> and  <a class="medical medical_review" href="/d/html/5949.html" rel="external">"Approach to the child with recurrent infections"</a> and  <a class="medical medical_review" href="/d/html/3951.html" rel="external">"Syndromic immunodeficiencies"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Measurement of serum IgG, IgA, and IgM, as well as specific antibodies.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Immunophenotyping and/or proliferative response to mitogens should be assessed in suspected cases in order to exclude cellular immunodeficiency or agammaglobulinemia (X linked or autosomal recessive).</p><p></p><p class="headingAnchor" id="H850226809"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>THI at presentation should be distinguished from other permanent forms of hypogammaglobulinemia [<a href="#rid2">2</a>]. Cases of X-linked or autosomal recessive agammaglobulinemia can be identified with relative ease by identifying low to absent B cells on flow cytometry and by confirming the diagnosis with genetic analysis [<a href="#rid43">43-45</a>]. However, more challenging are rare, leaky forms of these genetic defects that may present with circulating B cells, although antibody production is still aberrant [<a href="#rid46">46,47</a>]. (See  <a class="medical medical_review" href="/d/html/3937.html" rel="external">"Flow cytometry for the diagnosis of inborn errors of immunity", section on 'B cells'</a> and  <a class="medical medical_review" href="/d/html/3931.html" rel="external">"Agammaglobulinemia"</a> and  <a class="medical medical_review" href="/d/html/3914.html" rel="external">"Primary humoral immunodeficiencies: An overview"</a>.)</p><p>Early-onset common variable immunodeficiency (CVID) should also be considered in the differential diagnosis in patients after the age of two years. The common denominator with this heterogeneous group of patients is low immunoglobulins (IgG and IgA), but an inability to produce specific antibodies sets this condition apart from THI. The overlap in presentation between these disorders can be observed in patients with CVID who gradually lose the ability to form antibodies and cases with THI who initially lack antibodies but eventually resolve. (See  <a class="medical medical_review" href="/d/html/16132.html" rel="external">"Common variable immunodeficiency in children"</a>.)</p><p>Low immunoglobulins are also seen in patients with severe combined immunodeficiency. However, unlike THI, they distinctly present with very low lymphocyte counts, severe and recurrent viral or fungal infections, and failure to thrive. (See  <a class="medical medical_review" href="/d/html/3955.html" rel="external">"Severe combined immunodeficiency (SCID): An overview"</a>.)</p><p class="headingAnchor" id="H19"><span class="h1">OUTCOME</span><span class="headingEndMark"> — </span>By definition, THI should completely resolve, with return to normal serum immunoglobulin levels and response to immunizations by age four years [<a href="#rid48">48</a>]. Resolution of recurrent infections usually occurs by 9 to 15 months of age, while IgG levels typically normalize by two to four years of age [<a href="#rid8">8,29,31,48-50</a>]. Rarely, resolution may span up to three decades [<a href="#rid8">8,51</a>] and may include a transient phase during which IgG subclasses (especially IgG2) are temporarily low, although the utility of measuring IgG subclasses in this context clinically is unclear.</p><p class="headingAnchor" id="H20"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>Most patients with THI are observed and treated for infections as needed. However, patients with more frequent and/or more severe infections can be treated with antibiotic prophylaxis or <a class="drug drug_pediatric" data-topicid="83878" href="/d/drug information/83878.html" rel="external">immune globulin</a> replacement therapy.</p><p class="headingAnchor" id="H21"><span class="h2">Antibiotic prophylaxis</span><span class="headingEndMark"> — </span>Antibiotic prophylaxis is reserved for patients with recurrent respiratory and/or ear infections. The most commonly used options are a single daily dose of <a class="drug drug_pediatric" data-topicid="12816" href="/d/drug information/12816.html" rel="external">trimethoprim-sulfamethoxazole</a> (5 mg/kg of the <a class="drug drug_pediatric" data-topicid="12865" href="/d/drug information/12865.html" rel="external">trimethoprim</a> component), twice-daily <a class="drug drug_pediatric" data-topicid="12631" href="/d/drug information/12631.html" rel="external">amoxicillin</a> (20 mg/kg per dose), or <a class="drug drug_pediatric" data-topicid="12937" href="/d/drug information/12937.html" rel="external">azithromycin</a> (10 mg/kg weekly or 5 mg/kg every other day) [<a href="#rid17">17</a>]. (See  <a class="medical medical_review" href="/d/html/5998.html" rel="external">"Acute otitis media in children: Prevention of recurrence", section on 'Antibiotic prophylaxis'</a>.)</p><p class="headingAnchor" id="H22"><span class="h2">Immune globulin replacement therapy</span><span class="headingEndMark"> — </span>Most patients with THI have only mild infections and do not require <a class="drug drug_pediatric" data-topicid="83878" href="/d/drug information/83878.html" rel="external">immune globulin</a> replacement. Replacement therapy is reserved for patients with recurrent, severe infections who fail to respond to antibiotic prophylaxis [<a href="#rid48">48</a>]. (See  <a class="medical medical_review" href="/d/html/3911.html" rel="external">"Immune globulin therapy in inborn errors of immunity"</a> and  <a class="medical medical_review" href="/d/html/4431.html" rel="external">"Overview of intravenous immune globulin (IVIG) therapy"</a>.)</p><p><a class="drug drug_pediatric" data-topicid="83878" href="/d/drug information/83878.html" rel="external">Immune globulin</a> replacement therapy is used extensively, and the preparation has been shown to be safe [<a href="#rid46">46</a>]. Still, a decision to use this treatment should take the following into consideration:</p><p class="bulletIndent1"><span class="glyph">●</span>It is an expensive treatment.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>It is a blood product, and, as such, it may potentially transmit new and previously unrecognized infective agents despite extensive inactivation methods [<a href="#rid52">52</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mild adverse reactions are commonly associated with its administration. However, rarely, more severe reactions such as thromboembolic events have been reported. (See  <a class="medical medical_review" href="/d/html/3911.html" rel="external">"Immune globulin therapy in inborn errors of immunity"</a> and  <a class="medical medical_review" href="/d/html/3963.html" rel="external">"Selective IgA deficiency: Clinical manifestations, pathophysiology, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Administering <a class="drug drug_pediatric" data-topicid="83878" href="/d/drug information/83878.html" rel="external">immune globulin</a> replacement therapy may theoretically delay the endogenous synthesis of the patient's own immunoglobulins [<a href="#rid53">53</a>]. This was not observed among 43 patients with THI compared with 23 untreated controls [<a href="#rid48">48</a>].</p><p></p><p>Most patients with THI are treated with <a class="drug drug_pediatric" data-topicid="83878" href="/d/drug information/83878.html" rel="external">immune globulin</a> replacement therapy for short periods of time, ranging from a single injection up to 18 months of therapy [<a href="#rid12">12,22,54</a>]. Cessation of treatment is usually based upon the frequency and severity of infection and increase of immunoglobulins other than IgG. After discontinuation of therapy, patients should be followed periodically until a complete clinical and laboratory resolution is accomplished and sustained. (See <a class="local">'Diagnosis'</a> above.)</p><p class="headingAnchor" id="H962083373"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/112831.html" rel="external">"Society guideline links: Inborn errors of immunity (previously called primary immunodeficiencies)"</a>.)</p><p class="headingAnchor" id="H24"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition</strong> – Transient hypogammaglobulinemia of infancy (THI) is a diagnosis of exclusion that is established in retrospect after any laboratory findings and clinical manifestations have resolved. It occurs in the absence of other immunodeficiency conditions. Although transient, it persists beyond six months of age. (See <a class="local">'Introduction'</a> above and <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations</strong> – Patients with THI typically present in infancy with recurrent upper respiratory infections (URIs). Urinary tract infections, gastroenteritis, and invasive infections are less frequent. Some patients may be asymptomatic. Up to one-third of patients with THI have atopic features, including allergic respiratory features and food allergies. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Laboratory findings</strong> – Patients with THI have immunoglobulin G (IgG) levels that fall at least two standard deviations (SDs) below the mean for age-matched controls, with or without diminished values of other immunoglobulin isotypes. Specific antibodies to immunizations or infections are adequate in most patients at presentation and, in those with initially low levels, normalize with resolution of THI. (See <a class="local">'Laboratory findings'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis</strong> – The primary disorders to exclude are permanent forms of hypogammaglobulinemia, including X-linked or autosomal recessive agammaglobulinemia and common variable immunodeficiency (CVID). (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Outcome</strong> – Infections and immunoglobulin levels resolve in most patients by two to four years of age. Rarely, resolution may be delayed beyond the first decade of life. (See <a class="local">'Outcome'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antibiotic prophylaxis in patients with recurrent sinopulmonary infections</strong> – Antibiotic prophylaxis is reserved for patients with recurrent respiratory and/or ear infections. The most commonly used options are a single daily dose of <a class="drug drug_pediatric" data-topicid="12816" href="/d/drug information/12816.html" rel="external">trimethoprim-sulfamethoxazole</a> (5 mg/kg of the <a class="drug drug_pediatric" data-topicid="12865" href="/d/drug information/12865.html" rel="external">trimethoprim</a> component), twice-daily <a class="drug drug_pediatric" data-topicid="12631" href="/d/drug information/12631.html" rel="external">amoxicillin</a> (20 mg/kg per dose), or <a class="drug drug_pediatric" data-topicid="12937" href="/d/drug information/12937.html" rel="external">azithromycin</a> (10 mg/kg weekly or 5 mg/kg every other day). (See <a class="local">'Treatment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immune globulin</strong><strong> replacement therapy in patients with recurrent severe infections</strong> – <a class="drug drug_pediatric" data-topicid="83878" href="/d/drug information/83878.html" rel="external">Immune globulin</a> replacement therapy is reserved for patients with THI who have recurrent, severe infections and fail a trial of antibiotic prophylaxis. (See <a class="local">'Treatment'</a> above and  <a class="medical medical_review" href="/d/html/3911.html" rel="external">"Immune globulin therapy in inborn errors of immunity"</a>.)</p><p></p><p class="headingAnchor" id="H3803329425"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges E Richard Stiehm, MD, who contributed as a Section Editor to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">GITLIN D, JANEWAY CA. Agammaglobulinemia, congenital, acquired and transient forms. Prog Hematol 1956; 1:318.</a></li><li class="breakAll">McGeady SJ. Transient hypogammaglobulinemia of infancy. In: Stiehm's Immune Deficiencies, Stiehm ER (Ed), Elsevier Limited, Oxford 2014. p.417.</li><li><a class="nounderline abstract_t">Keles S, Artac H, Kara R, et al. Transient hypogammaglobulinemia and unclassified hypogammaglobulinemia: 'similarities and differences'. Pediatr Allergy Immunol 2010; 21:843.</a></li><li><a class="nounderline abstract_t">Tiller TL Jr, Buckley RH. Transient hypogammaglobulinemia of infancy: review of the literature, clinical and immunologic features of 11 new cases, and long-term follow-up. J Pediatr 1978; 92:347.</a></li><li><a class="nounderline abstract_t">Kiliç SS, Tezcan I, Sanal O, et al. Transient hypogammaglobulinemia of infancy: clinical and immunologic features of 40 new cases. Pediatr Int 2000; 42:647.</a></li><li><a class="nounderline abstract_t">Kidon MI, Handzel ZT, Schwartz R, et al. Symptomatic hypogammaglobulinemia in infancy and childhood - clinical outcome and in vitro immune responses. BMC Fam Pract 2004; 5:23.</a></li><li><a class="nounderline abstract_t">Whelan MA, Hwan WH, Beausoleil J, et al. Infants presenting with recurrent infections and low immunoglobulins: characteristics and analysis of normalization. J Clin Immunol 2006; 26:7.</a></li><li><a class="nounderline abstract_t">Dalal I, Reid B, Nisbet-Brown E, Roifman CM. The outcome of patients with hypogammaglobulinemia in infancy and early childhood. J Pediatr 1998; 133:144.</a></li><li><a class="nounderline abstract_t">Kowalczyk D, Mytar B, Zembala M. Cytokine production in transient hypogammaglobulinemia and isolated IgA deficiency. J Allergy Clin Immunol 1997; 100:556.</a></li><li><a class="nounderline abstract_t">Rutkowska M, Lenart M, Bukowska-Strakovà K, et al. The number of circulating CD4+ CD25high Foxp3+ T lymphocytes is transiently elevated in the early childhood of transient hypogammaglobulinemia of infancy patients. Clin Immunol 2011; 140:307.</a></li><li><a class="nounderline abstract_t">Bukowska-Straková K, Kowalczyk D, Baran J, et al. The B-cell compartment in the peripheral blood of children with different types of primary humoral immunodeficiency. Pediatr Res 2009; 66:28.</a></li><li><a class="nounderline abstract_t">Cano F, Mayo DR, Ballow M. Absent specific viral antibodies in patients with transient hypogammaglobulinemia of infancy. J Allergy Clin Immunol 1990; 85:510.</a></li><li><a class="nounderline abstract_t">Picard C, Bobby Gaspar H, Al-Herz W, et al. International Union of Immunological Societies: 2017 Primary Immunodeficiency Diseases Committee Report on Inborn Errors of Immunity. J Clin Immunol 2018; 38:96.</a></li><li><a class="nounderline abstract_t">Karaca NE, Aksu G, Gulez N, et al. New laboratory findings in Turkish patients with transient hypogammaglobulinemia of infancy. Iran J Allergy Asthma Immunol 2010; 9:237.</a></li><li><a class="nounderline abstract_t">Moschese V, Graziani S, Avanzini MA, et al. A prospective study on children with initial diagnosis of transient hypogammaglobulinemia of infancy: results from the Italian Primary Immunodeficiency Network. Int J Immunopathol Pharmacol 2008; 21:343.</a></li><li><a class="nounderline abstract_t">Moschese V, Cavaliere FM, Graziani S, et al. Decreased IgM, IgA, and IgG response to pneumococcal vaccine in children with transient hypogammaglobulinemia of infancy. J Allergy Clin Immunol 2016; 137:617.</a></li><li><a class="nounderline abstract_t">Bonilla FA, Khan DA, Ballas ZK, et al. Practice parameter for the diagnosis and management of primary immunodeficiency. J Allergy Clin Immunol 2015; 136:1186.</a></li><li><a class="nounderline abstract_t">Walker AM, Kemp AS, Hill DJ, Shelton MJ. Features of transient hypogammaglobulinaemia in infants screened for immunological abnormalities. Arch Dis Child 1994; 70:183.</a></li><li><a class="nounderline abstract_t">Qian JH, Zhu JX, Zhu XD, Chen TX. Clinical features and follow-up of Chinese patients with symptomatic hypogammaglobulinemia in infancy. Chin Med J (Engl) 2009; 122:1877.</a></li><li><a class="nounderline abstract_t">Kutukculer N, Gulez N. The outcome of patients with unclassified hypogammaglobulinemia in early childhood. Pediatr Allergy Immunol 2009; 20:693.</a></li><li><a class="nounderline abstract_t">McGeady SJ. Transient hypogammaglobulinemia of infancy: need to reconsider name and definition. J Pediatr 1987; 110:47.</a></li><li><a class="nounderline abstract_t">Dressler F, Peter HH, Müller W, Rieger CH. Transient hypogammaglobulinemia of infancy: Five new cases, review of the literature and redefinition. Acta Paediatr Scand 1989; 78:767.</a></li><li><a class="nounderline abstract_t">Siegel RL, Issekutz T, Schwaber J, et al. Deficiency of T helper cells in transient hypogammaglobulinemia of infancy. N Engl J Med 1981; 305:1307.</a></li><li><a class="nounderline abstract_t">FUDENBERG HH, FUDENBERG BR. ANTIBODY TO HEREDITARY HUMAN GAMMA-GLOBULIN (GM) FACTOR RESULTING FROM MATERNAL-FETAL INCOMPATIBILITY. Science 1964; 145:170.</a></li><li><a class="nounderline abstract_t">Soothill JF. Immunoglobulins in first-degree relatives of patients with hypogammaglobulinaemia. Transient hypogammaglobulinaemia: a possible manifestation of heterozygocity. Lancet 1968; 1:1001.</a></li><li><a class="nounderline abstract_t">Rieger CH, Nelson LA, Peri BA, et al. Transient hypogammaglobulinemia of infancy. J Pediatr 1977; 91:601.</a></li><li><a class="nounderline abstract_t">Lentz D, Gershwin ME. Is transient hypogammaglobulinemia of infancy a manifestation of zinc deficiency? Dev Comp Immunol 1984; 8:1.</a></li><li><a class="nounderline abstract_t">Rutkowska M, Trzyna E, Lenart M, et al. The elevated number of circulating regulatory T cells in patients with transient hypogammaglobulinemia of infancy is not associated with any abnormalities in the genes encoding the TGF-β receptors. Clin Immunol 2013; 149:83.</a></li><li class="breakAll">Wilson CB, Lewis DB, Penix LA. The physiologic immunodeficiency of immaturity. In: Immunologic disorders in infants and children, Stiehm ER (Ed), WB Saunders, Philadelphia 1996. p.253.</li><li><a class="nounderline abstract_t">Artac H, Kara R, Gokturk B, Reisli I. Reduced CD19 expression and decreased memory B cell numbers in transient hypogammaglobulinemia of infancy. Clin Exp Med 2013; 13:257.</a></li><li><a class="nounderline abstract_t">Dorsey MJ, Orange JS. Impaired specific antibody response and increased B-cell population in transient hypogammaglobulinemia of infancy. Ann Allergy Asthma Immunol 2006; 97:590.</a></li><li><a class="nounderline abstract_t">Eroglu FK, Aerts Kaya F, Cagdas D, et al. B lymphocyte subsets and outcomes in patients with an initial diagnosis of transient hypogammaglobulinemia of infancy. Scand J Immunol 2018; 88:e12709.</a></li><li><a class="nounderline abstract_t">van Zelm MC, Reisli I, van der Burg M, et al. An antibody-deficiency syndrome due to mutations in the CD19 gene. N Engl J Med 2006; 354:1901.</a></li><li><a class="nounderline abstract_t">Kutukculer N, Azarsiz E, Karaca NE, et al. Fcγ receptor polymorphisms in patients with transient hypogammaglobulinemia of infancy presenting with mild and severe infections. Asian Pac J Allergy Immunol 2015; 33:312.</a></li><li><a class="nounderline abstract_t">Cipe FE, Doğu F, Güloğlu D, et al. B-cell subsets in patients with transient hypogammaglobulinemia of infancy, partial IgA deficiency, and selective IgM deficiency. J Investig Allergol Clin Immunol 2013; 23:94.</a></li><li><a class="nounderline abstract_t">Pickett G, Motazedi T, Kutac C, et al. Infection Phenotypes Among Patients with Primary Antibody Deficiency Mined from a US Patient Registry. J Clin Immunol 2021; 41:374.</a></li><li><a class="nounderline abstract_t">Fineman SM, Rosen FS, Geha RS. Transient hypogammaglobulinemia, elevated immunoglobulin E levels, and food allergy. J Allergy Clin Immunol 1979; 64:216.</a></li><li><a class="nounderline abstract_t">Sumikawa Y, Kato J, Kan Y, et al. Severe atopic dermatitis associated with transient hypogammaglobulinemia of infancy. Int J Dermatol 2015; 54:e185.</a></li><li><a class="nounderline abstract_t">Moschese V, Carsetti R, Graziani S, et al. Memory B-cell subsets as a predictive marker of outcome in hypogammaglobulinemia during infancy. J Allergy Clin Immunol 2007; 120:474.</a></li><li><a class="nounderline abstract_t">Alachkar H, Taubenheim N, Haeney MR, et al. Memory switched B cell percentage and not serum immunoglobulin concentration is associated with clinical complications in children and adults with specific antibody deficiency and common variable immunodeficiency. Clin Immunol 2006; 120:310.</a></li><li><a class="nounderline abstract_t">Carsetti R, Rosado MM, Donnanno S, et al. The loss of IgM memory B cells correlates with clinical disease in common variable immunodeficiency. J Allergy Clin Immunol 2005; 115:412.</a></li><li><a class="nounderline abstract_t">Emsen A, Uçaryılmaz H, Güler T, Artaç H. Regulatory T and B cells in transient hypogammaglobulinemia of infancy. Turk J Pediatr 2022; 64:228.</a></li><li><a class="nounderline abstract_t">Buckley RH. Immunodeficiency diseases. JAMA 1992; 268:2797.</a></li><li><a class="nounderline abstract_t">Iseki M, Heiner DC. Immunodeficiency disorders. Pediatr Rev 1993; 14:226.</a></li><li><a class="nounderline abstract_t">Vetrie D, Vorechovský I, Sideras P, et al. The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases. Nature 1993; 361:226.</a></li><li><a class="nounderline abstract_t">Kornfeld SJ, Kratz J, Haire RN, et al. X-linked agammaglobulinemia presenting as transient hypogammaglobulinemia of infancy. J Allergy Clin Immunol 1995; 95:915.</a></li><li><a class="nounderline abstract_t">Saffran DC, Parolini O, Fitch-Hilgenberg ME, et al. Brief report: a point mutation in the SH2 domain of Bruton's tyrosine kinase in atypical X-linked agammaglobulinemia. N Engl J Med 1994; 330:1488.</a></li><li><a class="nounderline abstract_t">Memmedova L, Azarsiz E, Edeer Karaca N, et al. Does intravenous immunoglobulin therapy prolong immunodeficiency in transient hypogammaglobulinemia of infancy? Pediatr Rep 2013; 5:e14.</a></li><li><a class="nounderline abstract_t">Rosen FS, Janeway CA. The gamma globulins. 3. The antibody deficiency syndromes. N Engl J Med 1966; 275:769.</a></li><li><a class="nounderline abstract_t">Doğu F, Ikincioğullari A, Babacan E. Transient hypogammaglobulinemia of infancy and early childhood: outcome of 30 cases. Turk J Pediatr 2004; 46:120.</a></li><li><a class="nounderline abstract_t">Ameratunga R, Ahn Y, Steele R, Woon ST. Transient hypogammaglobulinaemia of infancy: many patients recover in adolescence and adulthood. Clin Exp Immunol 2019; 198:224.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Outbreak of hepatitis C associated with intravenous immunoglobulin administration--United States, October 1993-June 1994. MMWR Morb Mortal Wkly Rep 1994; 43:505.</a></li><li><a class="nounderline abstract_t">Rosen FS, Cooper MD, Wedgwood RJ. The primary immunodeficiencies (1). N Engl J Med 1984; 311:235.</a></li><li><a class="nounderline abstract_t">Duse M, Iacobini M, Leonardi L, et al. Transient hypogammaglobulinemia of infancy: intravenous immunoglobulin as first line therapy. Int J Immunopathol Pharmacol 2010; 23:349.</a></li></ol></div><div id="topicVersionRevision">Topic 5951 Version 20.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13359516" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Agammaglobulinemia, congenital, acquired and transient forms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13359516" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Agammaglobulinemia, congenital, acquired and transient forms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20609138" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Transient hypogammaglobulinemia and unclassified hypogammaglobulinemia: 'similarities and differences'.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/632973" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Transient hypogammaglobulinemia of infancy: review of the literature, clinical and immunologic features of 11 new cases, and long-term follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11192522" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Transient hypogammaglobulinemia of infancy: clinical and immunologic features of 40 new cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15498106" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Symptomatic hypogammaglobulinemia in infancy and childhood - clinical outcome and in vitro immune responses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16418798" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Infants presenting with recurrent infections and low immunoglobulins: characteristics and analysis of normalization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9672529" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : The outcome of patients with hypogammaglobulinemia in infancy and early childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9338552" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Cytokine production in transient hypogammaglobulinemia and isolated IgA deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21531630" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : The number of circulating CD4+ CD25high Foxp3+ T lymphocytes is transiently elevated in the early childhood of transient hypogammaglobulinemia of infancy patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19342988" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : The B-cell compartment in the peripheral blood of children with different types of primary humoral immunodeficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2303650" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Absent specific viral antibodies in patients with transient hypogammaglobulinemia of infancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29226302" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : International Union of Immunological Societies: 2017 Primary Immunodeficiency Diseases Committee Report on Inborn Errors of Immunity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21131704" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : New laboratory findings in Turkish patients with transient hypogammaglobulinemia of infancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18547478" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : A prospective study on children with initial diagnosis of transient hypogammaglobulinemia of infancy: results from the Italian Primary Immunodeficiency Network.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26233927" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Decreased IgM, IgA, and IgG response to pneumococcal vaccine in children with transient hypogammaglobulinemia of infancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26371839" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Practice parameter for the diagnosis and management of primary immunodeficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8135560" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Features of transient hypogammaglobulinaemia in infants screened for immunological abnormalities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19781364" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Clinical features and follow-up of Chinese patients with symptomatic hypogammaglobulinemia in infancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19196447" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : The outcome of patients with unclassified hypogammaglobulinemia in early childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3794886" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Transient hypogammaglobulinemia of infancy: need to reconsider name and definition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2596283" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Transient hypogammaglobulinemia of infancy: Five new cases, review of the literature and redefinition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6270560" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Deficiency of T helper cells in transient hypogammaglobulinemia of infancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14171557" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : ANTIBODY TO HEREDITARY HUMAN GAMMA-GLOBULIN (GM) FACTOR RESULTING FROM MATERNAL-FETAL INCOMPATIBILITY.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4171800" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Immunoglobulins in first-degree relatives of patients with hypogammaglobulinaemia. Transient hypogammaglobulinaemia: a possible manifestation of heterozygocity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/908979" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Transient hypogammaglobulinemia of infancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6233190" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Is transient hypogammaglobulinemia of infancy a manifestation of zinc deficiency?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23899993" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : The elevated number of circulating regulatory T cells in patients with transient hypogammaglobulinemia of infancy is not associated with any abnormalities in the genes encoding the TGF-βreceptors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23899993" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : The elevated number of circulating regulatory T cells in patients with transient hypogammaglobulinemia of infancy is not associated with any abnormalities in the genes encoding the TGF-βreceptors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22820757" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Reduced CD19 expression and decreased memory B cell numbers in transient hypogammaglobulinemia of infancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17165264" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Impaired specific antibody response and increased B-cell population in transient hypogammaglobulinemia of infancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30152873" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : B lymphocyte subsets and outcomes in patients with an initial diagnosis of transient hypogammaglobulinemia of infancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16672701" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : An antibody-deficiency syndrome due to mutations in the CD19 gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26708396" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Fcγreceptor polymorphisms in patients with transient hypogammaglobulinemia of infancy presenting with mild and severe infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23654075" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : B-cell subsets in patients with transient hypogammaglobulinemia of infancy, partial IgA deficiency, and selective IgM deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33205244" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Infection Phenotypes Among Patients with Primary Antibody Deficiency Mined from a US Patient Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/89129" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Transient hypogammaglobulinemia, elevated immunoglobulin E levels, and food allergy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25600656" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Severe atopic dermatitis associated with transient hypogammaglobulinemia of infancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17531302" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Memory B-cell subsets as a predictive marker of outcome in hypogammaglobulinemia during infancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16782407" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Memory switched B cell percentage and not serum immunoglobulin concentration is associated with clinical complications in children and adults with specific antibody deficiency and common variable immunodeficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15696104" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : The loss of IgM memory B cells correlates with clinical disease in common variable immunodeficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35611411" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Regulatory T and B cells in transient hypogammaglobulinemia of infancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1433695" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Immunodeficiency diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8327399" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Immunodeficiency disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8380905" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7722175" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : X-linked agammaglobulinemia presenting as transient hypogammaglobulinemia of infancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8164701" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Brief report: a point mutation in the SH2 domain of Bruton's tyrosine kinase in atypical X-linked agammaglobulinemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24198926" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Does intravenous immunoglobulin therapy prolong immunodeficiency in transient hypogammaglobulinemia of infancy?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5332147" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : The gamma globulins. 3. The antibody deficiency syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15214739" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Transient hypogammaglobulinemia of infancy and early childhood: outcome of 30 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31260083" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Transient hypogammaglobulinaemia of infancy: many patients recover in adolescence and adulthood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8022396" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Outbreak of hepatitis C associated with intravenous immunoglobulin administration--United States, October 1993-June 1994.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6234467" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : The primary immunodeficiencies (1).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20378022" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Transient hypogammaglobulinemia of infancy: intravenous immunoglobulin as first line therapy.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
